Related Experiment Videos
Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation
1Department of Virology, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill Street, Hampstead NW3 2QG, UK. v.emery@rfc.ucl.ac.uk
Reviews in Medical Virology
|March 23, 2001
Summary
Pre-emptive therapy for human cytomegalovirus (HCMV) infection, guided by sensitive detection methods, targets high-risk patients effectively. This approach minimizes drug exposure and cost while priming the immune system for better long-term HCMV control.
Area of Science:
- Virology
- Immunology
- Pharmacology
Background:
- Human cytomegalovirus (HCMV) infection poses significant risks, particularly in immunocompromised individuals.
- Current management strategies for HCMV infection include pre-emptive therapy (PET) and prophylaxis.
- Sensitive diagnostic methods like PCR and antigenaemia are crucial for early HCMV detection.
Discussion:
- Pre-emptive therapy (PET) targets antiviral treatment based on HCMV detection, optimizing drug use for high-risk patients.
- PET minimizes exposure to potentially toxic antiviral drugs compared to universal prophylaxis.
- Allowing limited HCMV replication during PET can stimulate the immune system, aiding future viral control.
Key Insights:
- PET allows for targeted antiviral therapy, reducing drug exposure and improving cost-effectiveness.
- Immune stimulation from limited HCMV replication during PET is beneficial for long-term viral management.
- Prophylaxis is a costly strategy with potential toxicity, failing to prime the immune system and risking late HCMV disease.
Outlook:
- Further research into optimizing PET protocols based on sensitive HCMV detection is warranted.
- Evaluating the long-term immunological benefits of PET compared to prophylaxis will be crucial.
- Investigating cost-benefit analyses of PET versus prophylaxis in diverse patient populations is essential.